When Food Becomes Opioid:How Casein- and Gluten-Derived Exorphins May Blunt the Effectiveness of Low Dose Naltrexone

Yoon Hang "John" Kim, MD, MPH

www.directintegrativecare.com

Abstract

Low dose naltrexone (LDN) is widely used in integrative medicine for autoimmune disease, chronic pain, fibromyalgia, inflammatory bowel disease, and select malignancies. Its therapeutic effect is generally attributed to a brief, transient blockade of opioid receptors that triggers compensatory upregulation of endogenous opioids, opioid receptors, and the opioid growth factor (OGF) axis, together with antagonism of toll-like receptor 4 (TLR4) on microglia. A growing body of biochemistry and food-science literature demonstrates that incomplete digestion of bovine A1 β-casein and wheat gluten releases bioactive opioid peptides—β-casomorphin-7 (BCM-7) and the gluten exorphins (including gliadorphin-7)—that act as μ- and δ-opioid receptor agonists in vitro and in vivo. This article reviews the mechanistic plausibility that chronic dietary exposure to these exogenous opioid peptides (“exorphins”) may attenuate the rebound endorphin response central to LDN’s mechanism, particularly in patients with intestinal hyperpermeability or diminished dipeptidyl peptidase-IV (DPP-IV) activity. The current evidence is mechanistic and indirect; no randomized trial has formally tested an exorphin–LDN interaction. Nevertheless, the convergence of pharmacology and clinical experience justifies a trial of dairy and gluten restriction in LDN patients with suboptimal response.

Introduction

Low dose naltrexone has moved from off-label curiosity to a recognized tool in integrative and functional medicine. At doses of 1.5 to 4.5 mg taken at bedtime, naltrexone produces a brief opioid-receptor blockade lasting roughly four to six hours, after which the body compensates by upregulating endorphins, met-enkephalin (also called opioid growth factor, or OGF), and their receptors. This compensatory rebound is widely cited as the molecular basis for LDN’s analgesic, anti-inflammatory, and immunomodulatory effects (Toljan & Vrooman, 2018; Trofimovitch & Baumrucker, 2019).

Yet many experienced LDN prescribers observe a familiar pattern: a subset of carefully titrated patients fail to derive the expected benefit, even after months of therapy and dose optimization. Common explanations include the presence of exogenous opioids, untreated infection, comorbid mast cell activation, inadequate sleep, or pharmacy-related quality issues. An additional and often-overlooked variable is dietary: the patient may be taking LDN every evening while also consuming a steady stream of food-derived opioid peptides every day.

This article reviews the molecular biology of two of the most studied dietary exorphin families—β-casomorphins from bovine A1 β-casein, and the gluten exorphins (including gliadorphin-7) from wheat, barley, and rye—and lays out the mechanistic case for why their chronic ingestion may compete with, or attenuate, the rebound effect on which LDN depends.

A Brief Refresher: How LDN Is Believed to Work

Naltrexone is a competitive antagonist at μ-, δ-, and κ-opioid receptors, with highest affinity for the μ-opioid receptor (MOR). At the standard 50 mg dose used in opioid and alcohol use disorder, naltrexone produces near-continuous receptor blockade for 24 hours. At doses approximately one-tenth to one-twentieth of standard, the blockade is intermittent rather than sustained—a key distinction that gives LDN its therapeutic profile (Toljan & Vrooman, 2018).

Three mechanisms are typically invoked. First, the transient receptor blockade is interpreted by the central nervous system as an endorphin deficiency, prompting upregulation of endorphin and met-enkephalin synthesis along with increased μ-opioid and OGF receptor density (Cant et al., 2017; Toljan & Vrooman, 2018). Second, naltrexone antagonizes TLR4 signaling on microglia and peripheral macrophages, suppressing release of TNF-α, IL-6, and IL-1β and reducing neuroinflammation (Cant et al., 2017; Hutchinson et al., 2008). Third, the OGF/OGF-receptor axis is engaged, producing tonic inhibition of cell proliferation that underlies LDN’s explored role in oncology (Zagon & McLaughlin, 2018).

It is fair to note that the rebound endorphin model is not without challengers. Patten and colleagues (2018) failed to detect consistent increases in proopiomelanocortin (POMC) neuronal activity or plasma β-endorphin in LDN-treated mice, suggesting that some of the clinical effect may be mediated by TLR4 antagonism and OGF signaling rather than β-endorphin per se. Even with that caveat, the central premise—that LDN works through a delicate, time-limited interaction with the opioid system—remains intact, and is precisely what makes the system vulnerable to interference from chronically circulating opioid agonists.

Food as a Source of Opioid-Active Peptides

The notion that dietary proteins can give rise to morphine-like compounds dates to the late 1970s, when Zioudrou and colleagues (1979) demonstrated that peptic digests of wheat gluten exert opioid activity in the electrically stimulated mouse vas deferens preparation. They named these peptides “exorphins”—exogenous, food-derived analogs of endogenous endorphins. Casomorphins from milk casein were characterized in the same era. Both peptide families share several features: a tyrosine residue at the N-terminus (mimicking the tyrosine that anchors enkephalins to the opioid receptor), proline-rich sequences that resist ordinary digestion, and demonstrated affinity for μ- and/or δ-opioid receptors (Liu & Udenigwe, 2018).

β-Casomorphin-7: The A1 Milk Story

Bovine β-casein exists in two principal genetic variants, A1 and A2, distinguished by a single amino acid at position 67 of the mature protein. A1 β-casein contains histidine at this position; A2 β-casein contains proline. The histidine variant permits enzymatic cleavage between residues 66 and 67 by gastrointestinal peptidases, releasing the heptapeptide β-casomorphin-7 (BCM-7; Tyr-Pro-Phe-Pro-Gly-Pro-Ile). The A2 variant is largely resistant to this cleavage (Cieślińska et al., 2022; Daniloski et al., 2024). Most commercially available milk in North America and northern Europe contains A1 or mixed A1/A2 β-casein, and therefore yields BCM-7 upon digestion.

BCM-7 is a recognized μ-opioid receptor agonist. Its analgesic effect in animal models persists for 90 minutes or longer—substantially longer than the shorter casomorphins BCM-4 through BCM-6 (Daniloski et al., 2024). Once formed, BCM-7 can pass through the human intestinal barrier into systemic circulation, particularly when intestinal permeability is increased or when DPP-IV activity is reduced (Cieślińska et al., 2022; Trivedi et al., 2014). DPP-IV is the principal enzyme responsible for BCM-7 degradation; its activity is genetically variable and is reduced in celiac disease, atopic dermatitis, and a subset of children with neurodevelopmental disorders (Cieślińska et al., 2014).

Gluten Exorphins and Gliadorphin-7

Wheat gluten consists of two protein fractions—gliadins (alcohol-soluble) and glutenins (alcohol-insoluble). Both are unusually rich in proline and glutamine, making them resistant to hydrolysis by human pancreatic and brush-border peptidases (Pruimboom & de Punder, 2015). Incomplete digestion releases at least seven characterized opioid peptides: gluten exorphin A4, A5, B4, B5, C5, gliadorphin-7 (also called gluteomorphin or gluten exorphin-7; Tyr-Pro-Gln-Pro-Gln-Pro-Phe), and its deamidated form. Gluten exorphin B5 (Tyr-Gly-Gly-Trp-Leu) is structurally similar to leu-enkephalin and is among the most potent in vitro, with agonist activity at both μ- and δ-opioid receptors (Fanciulli et al., 2005; Liu & Udenigwe, 2018).

Pruimboom and de Punder (2015) proposed the “silent opioid hypothesis” to explain why some patients with biopsy-proven celiac disease lack classical gastrointestinal symptoms: the opioid effects of gluten exorphins on intestinal motility and visceral pain perception may mask the underlying enteropathy. The same authors note that gluten-derived peptides also inhibit DPP-IV, prolonging the half-life of casomorphins and other proline-rich peptides—a potentially additive effect when dairy and gluten are co-ingested. In vitro intestinal models confirm that gluten exorphins A5 and C5 are released during simulated gastrointestinal digestion of bread and pasta and are absorbed across Caco-2/HT-29 epithelial co-cultures (Taraszkiewicz et al., 2015).

Why This Matters for LDN

LDN’s clinical effect depends on a narrow choreography. A small dose of naltrexone occupies opioid receptors briefly; the body interprets this transient occupancy as a signal of opioid deficiency; receptor density and endogenous opioid synthesis rise; and the patient benefits from the resulting sustained increase in endogenous opioid tone, OGF activity, and TLR4 quieting. Anything that maintains a chronic baseline of opioid agonism on those same receptors will, in principle, attenuate the perceived deficit—and therefore the rebound.

Pharmacologic Competition at the Receptor

Casomorphins and gluten exorphins share the binding pocket that LDN exploits. Although their individual affinities are lower than those of endogenous endorphins or pharmaceutical opioids, their cumulative effect across multiple daily exposures is plausible (Liu & Udenigwe, 2018; Garg et al., 2024). Patients who eat dairy at breakfast, a sandwich at lunch, and pasta at dinner are presenting their μ-opioid system with a near-continuous trickle of partial agonists. This is conceptually the opposite of the brief, deliberate blockade that LDN is designed to produce. The net result, in a susceptible individual, may resemble “opioid noise”: a low-grade tonic agonism that the central nervous system stops registering as worth responding to.

DPP-IV Bottlenecks and the Permeability Question

Whether dietary exorphins reach systemic circulation depends on two factors: how well DPP-IV degrades them at the brush border, and how intact the intestinal barrier is. Both are frequently compromised in the same patient populations who reach for LDN. Celiac disease, non-celiac gluten sensitivity, inflammatory bowel disease, and autoimmune conditions associated with elevated zonulin all increase intestinal permeability (Fasano, 2020). Atopic disease, celiac disease, and certain medications reduce DPP-IV activity (Cieślińska et al., 2014). These are precisely the patients in whom dietary exorphins are most likely to enter circulation in pharmacologically relevant amounts—and they are also the patients most often prescribed LDN.

Microbiome and Gut–Brain Axis Effects

Beyond direct receptor competition, dietary exorphins influence the same gut–brain pathways that LDN modulates. BCM-7 and gluten exorphins alter intestinal motility, mucus production, and microbiome composition through opioid-receptor–mediated mechanisms (Garg et al., 2024; Trivedi et al., 2014). Chronic exposure to BCM-7 has been associated, in animal models, with increased oxidative stress, altered cysteine uptake, and downstream epigenetic effects on methylation pathways (Trivedi et al., 2014). These broader effects do not contradict the receptor-competition model; they extend it, providing additional mechanisms by which dietary exorphins may flatten the inflammatory and immune signal that LDN is meant to modulate.

What the Evidence Does and Does Not Show

Intellectual honesty requires precision here. To this author’s knowledge, no randomized controlled trial has directly tested whether dairy or gluten elimination potentiates the effect of LDN. The case rests on three converging bodies of evidence:

Pharmacology. BCM-7 and gluten exorphins are confirmed opioid receptor agonists in vitro and in animal models, and at least some can cross the human intestinal barrier (Cieślińska et al., 2022; Fanciulli et al., 2005; Liu & Udenigwe, 2018).

Clinical correlation. Dietary opioid peptides have been associated, with varying levels of evidence, with atopic dermatitis, gastrointestinal dysmotility, neurodevelopmental disorders, and celiac/non-celiac gluten sensitivity (Cieślińska et al., 2014; Pruimboom & de Punder, 2015). The European Food Safety Authority (2009) reviewed the topic and concluded that while a definitive causal role in chronic disease has not been established in humans, the mechanistic plausibility is real and warrants ongoing study.

Clinical experience. Many integrative practitioners, this author included, observe that LDN responses frequently improve when patients adopt a strict gluten-free, casein-free trial, particularly in autoimmune, fibromyalgia, and ME/CFS populations. This observation has not been formally tested but is consistent across enough independent practices to deserve investigation.

The reader should weigh these caveats explicitly. Mechanistic plausibility is not proof, and absence of a controlled trial is not the same as a negative trial. The reasonable clinical stance is to consider this hypothesis a working model—useful for guiding individual trials of elimination diet, but not yet established as standard of care.

Practical Implications for the LDN Patient

Several practical considerations follow. First, in patients beginning LDN—especially those with autoimmune, neuroinflammatory, or fibromyalgia indications—a four- to twelve-week trial of strict gluten and casein elimination is reasonable, low risk, and inexpensive. The author typically asks patients to remove all wheat, barley, rye, and conventional A1-containing dairy for a defined period, with careful symptom tracking before and after. A2-only milk and fermented dairy with low BCM-7 release may be tolerated by some, but a strict elimination phase yields a clearer signal.

Second, patients with established intestinal barrier dysfunction—celiac disease, IBD, post-infectious states, or elevated zonulin—deserve particular attention to gut barrier support alongside LDN. Strategies that address tight junction integrity, microbiome diversity, and DPP-IV activity (whether through diet, targeted enzymes, or peptide therapeutics where appropriate and available) may indirectly support LDN response.

Third, clinicians should not be too quick to escalate the LDN dose in non-responders without first auditing the dietary environment. A patient who is not responding at 4.5 mg may not need 6 mg; the patient may need to stop pouring exorphins onto the receptor every six hours. Dose escalation in the absence of a clean dietary baseline can produce sleep disturbance, vivid dreams, and other tolerability issues without delivering the hoped-for clinical benefit.

Finally, patients should be counseled that this is a hypothesis-driven recommendation rather than a guaranteed mechanism. The goal is empirical: try the diet, measure the response, and decide what to do next based on the patient’s actual experience.

Conclusion

Low dose naltrexone is most useful in patients whose endogenous opioid system has the capacity to rebound. Chronic dietary exposure to bovine A1 β-casein and wheat gluten produces opioid-active peptides—β-casomorphin-7 and the gluten exorphins—that engage the same receptors LDN transiently blocks. In susceptible patients with intestinal hyperpermeability or reduced DPP-IV activity, this pharmacologic background noise is biologically plausible as a mechanism of LDN underperformance. The evidence for a direct food–LDN interaction remains mechanistic and indirect, but the cost and risk of a structured elimination trial are low, and the potential clinical yield is high. For the patient who has done everything “right” and still does not feel the LDN, the cup of milk in the morning coffee and the slice of bread at lunch may be a reasonable next place to look.

References

Cant, R., Dalgleish, A. G., & Allen, R. L. (2017). Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors. Frontiers in Immunology, 8, 809. https://doi.org/10.3389/fimmu.2017.00809  [PMID: 28744288]

Cieślińska, A., Fiedorowicz, E., Zwierzchowski, G., Kordulewska, N., Jarmołowska, B., & Kostyra, E. (2022). Genetic polymorphism of β-casein gene in Polish red cattle—preliminary study of A1 and A2 frequency in genetic conservation herd. International Journal of Molecular Sciences, 23(7), 4054. https://doi.org/10.3390/ijms23074054  [PMID: 35409414]

Cieślińska, A., Sienkiewicz-Szłapka, E., Wasilewska, J., Fiedorowicz, E., Chwała, B., Moszyńska-Dumara, M., Cieśliński, T., Bukało, M., & Kostyra, E. (2014). β-casomorphin-7 alters μ-opioid receptor and dipeptidyl peptidase IV genes expression in children with atopic dermatitis. Peptides, 65, 6–11. https://doi.org/10.1016/j.peptides.2014.11.002  [PMID: 25281794]

Daniloski, D., McCarthy, N. A., & Vasiljevic, T. (2024). β-casomorphin-7: A potential therapeutic peptide for chronic disease management—an opinion. Molecules, 29(9), 2161. https://doi.org/10.3390/molecules29092161  [PMID: 38731651]

European Food Safety Authority (EFSA). (2009). Review of the potential health impact of β-casomorphins and related peptides. EFSA Journal, 7(2), 231r. https://doi.org/10.2903/j.efsa.2009.231r

Fanciulli, G., Dettori, A., Demontis, M. P., Tomasi, P. A., Anania, V., & Delitala, G. (2005). Gluten exorphin B5 stimulates prolactin secretion through opioid receptors located outside the blood-brain barrier. Life Sciences, 76(15), 1713–1719. https://doi.org/10.1016/j.lfs.2004.09.023  [PMID: 15698851]

Fasano, A. (2020). All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Research, 9, F1000 Faculty Rev-69. https://doi.org/10.12688/f1000research.20510.1  [PMID: 32051759]

Garg, S., Forester, S., Liu, Y., & Lupien-Meilleur, J. (2024). Casomorphins and gliadorphins have diverse systemic effects spanning gut, brain and internal organs. International Journal of Environmental Research and Public Health, 18(15), 7911. https://doi.org/10.3390/ijerph18157911  [PMID: 34360205]

Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). European Journal of Neuroscience, 28(1), 20–29. https://doi.org/10.1111/j.1460-9568.2008.06321.x  [PMID: 18662331]

Liu, Z., & Udenigwe, C. C. (2018). Role of food-derived opioid peptides in the central nervous and gastrointestinal systems. Journal of Food Biochemistry, 43(1), e12629. https://doi.org/10.1111/jfbc.12629  [PMID: 31353508]

Patten, D. K., Schultz, B. G., & Berlau, D. J. (2018). The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy, 38(3), 382–389. https://doi.org/10.1002/phar.2086  [PMID: 29377216]

Pruimboom, L., & de Punder, K. (2015). The opioid effects of gluten exorphins: Asymptomatic celiac disease. Journal of Health, Population and Nutrition, 33, 24. https://doi.org/10.1186/s41043-015-0032-y  [PMID: 26825414]

Taraszkiewicz, A., Sinkiewicz, I., Sommer, A., Dąbrowska, M., & Staroszczyk, H. (2015). Release of wheat gluten exorphins A5 and C5 during in vitro gastrointestinal digestion of bread and pasta and their absorption through an in vitro model of intestinal epithelium. Food Research International, 73, 168–175. https://doi.org/10.1016/j.foodres.2015.03.029

Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences, 6(4), 82. https://doi.org/10.3390/medsci6040082  [PMID: 30248938]

Trivedi, M. S., Shah, J. S., Al-Mughairy, S., Hodgson, N. W., Simms, B., Trooskens, G. A., Van Criekinge, W., & Deth, R. C. (2014). Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. Journal of Nutritional Biochemistry, 25(10), 1011–1018. https://doi.org/10.1016/j.jnutbio.2014.05.004  [PMID: 25018147]

Trofimovitch, D., & Baumrucker, S. J. (2019). Pharmacology update: Low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes. American Journal of Hospice and Palliative Medicine, 36(10), 907–912. https://doi.org/10.1177/1049909119838974  [PMID: 30917675]

Zagon, I. S., & McLaughlin, P. J. (2018). The biology of the opioid growth factor receptor (OGFr). Brain Research Reviews, 38(3), 351–376. https://doi.org/10.1016/s0165-0173(01)00160-6  [PMID: 11890981]

Zioudrou, C., Streaty, R. A., & Klee, W. A. (1979). Opioid peptides derived from food proteins. The exorphins. Journal of Biological Chemistry, 254(7), 2446–2449. https://doi.org/10.1016/S0021-9258(17)30243-0  [PMID: 372181]